Testing efimosfermin for MASH with compensated cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have MASH that has caused cirrhosis (liver scarring), confirmed by non-invasive tests.
- You have at least 2 signs of metabolic syndrome, such as high blood pressure, high blood sugar, high cholesterol, or carrying extra belly fat.
- You do not have other types of liver disease or any past liver failure or liver cancer.
- You do not have type 1 diabetes or major complications from type 2 diabetes.
- You do not have a history of heavy alcohol use or drink excessively now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, efimosfermin, to see if it is safe and effective for people with cirrhosis caused by MASH (a type of fatty liver disease). It may help improve liver health compared to a placebo.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This trial tests a new experimental drug called OPK-88006 to see if it can help treat MASH, a serious liver condition linked to excess fat buildup. The study has two parts: one with healthy volunteers to check safety, and one with people who have signs of fatty liver disease.
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Hear when a new Metabolic Dysfunction-associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.